Paradigm Financial Partners LLC Has $1.99 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Paradigm Financial Partners LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 227.1% in the 4th quarter, Holdings Channel reports. The institutional investor owned 4,896 shares of the pharmaceutical company’s stock after acquiring an additional 3,399 shares during the period. Paradigm Financial Partners LLC’s holdings in Vertex Pharmaceuticals were worth $1,992,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sherbrooke Park Advisers LLC lifted its holdings in Vertex Pharmaceuticals by 65.3% in the 3rd quarter. Sherbrooke Park Advisers LLC now owns 2,645 shares of the pharmaceutical company’s stock worth $920,000 after purchasing an additional 1,045 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its position in shares of Vertex Pharmaceuticals by 6.5% during the third quarter. Robeco Institutional Asset Management B.V. now owns 432,937 shares of the pharmaceutical company’s stock valued at $150,550,000 after purchasing an additional 26,523 shares during the period. Telos Capital Management Inc. boosted its stake in Vertex Pharmaceuticals by 1.6% in the 4th quarter. Telos Capital Management Inc. now owns 15,073 shares of the pharmaceutical company’s stock valued at $6,133,000 after buying an additional 237 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Vertex Pharmaceuticals by 1.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 427,001 shares of the pharmaceutical company’s stock valued at $148,485,000 after buying an additional 5,514 shares in the last quarter. Finally, Machina Capital S.A.S. acquired a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at $816,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the transaction, the executive vice president now directly owns 74,364 shares in the company, valued at $31,250,727.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Trading Down 0.1 %

Shares of Vertex Pharmaceuticals stock traded down $0.22 during trading hours on Friday, hitting $397.48. The company’s stock had a trading volume of 682,467 shares, compared to its average volume of 909,553. Vertex Pharmaceuticals Incorporated has a 12 month low of $320.01 and a 12 month high of $448.40. The stock has a 50 day moving average of $411.60 and a 200 day moving average of $398.93. The company has a market capitalization of $102.73 billion, a PE ratio of 28.62, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. The business had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same period last year, the company earned $3.33 earnings per share. Analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their price objective on Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Maxim Group lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Canaccord Genuity Group lowered Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and boosted their price objective for the stock from $332.00 to $379.00 in a research note on Wednesday, January 24th. StockNews.com lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 20th. Finally, Barclays upped their price target on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $429.45.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.